News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Antero Resources expects materially higher free cash flow in H2 2026.
  • Shares trade around $34.92, implying a steep discount to historical cyclic peaks.
  • Debt/equity stands near 0.31, reducing leverage risk.
  • EV/EBITDA sits near 6, pointing to a cheap valuation.
  • Report outlines entry, stop and target for a 180 trading-day horizon.

Latest Articles

SoFi Raises 2026 Revenue Outlook After Record Member and Loan Growth

SoFi Raises 2026 Revenue Outlook After Record Member and Loan Growth

SoFi updated its full-year revenue target for 2026 after reporting a robust second quarter marked by record member additions and loan originations. Revenue and net interest income accelerated sharply year-over-year, while management highlighted resilient consumer credit performance amid a challenging macro backdrop.

Anika Reports Second Quarter 2026 Financial Results

Anika Reports Second Quarter 2026 Financial Results

Anika Therapeutics, a leader in osteoarthritis pain management and orthopedic regenerative solutions, announced strong Q2 2026 financial results with record Commercial Channel revenue growth of 17% to $13.9 million, gross margin expansion to 65%, and adjusted EBITDA of $7.1 million, the highest since 2020. The company raised its full-year 2026 reve…

Axogen, Inc. Reports Second Quarter 2026 Financial Results

Axogen, Inc. Reports Second Quarter 2026 Financial Results

Axogen, Inc., a leader in peripheral nerve repair solutions, reported Q2 2026 revenue of $69.7 million, up 23.1% year-over-year. Despite a GAAP net loss of $1.5 million, adjusted net income increased to $7.3 million. The company is advancing clinical studies providing Level 1 evidence for its nerve repair products and expanded commercial coverage. …

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Ocugen announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy candidate OCU410 aimed at treating geographic atrophy secondary to dry age-related macular degeneration (dAMD). The designation supports expedited development and regulatory review due to promising Phase 2 clinical data demonstrating e…

Lightbridge Corporation Added to the Solactive Global Uranium & Nuclear Components Total Return Index, the Benchmark Tracked by the Global X Uranium ETF (URA)

Lightbridge Corporation Added to the Solactive Global Uranium & Nuclear Components Total Return Index, the Benchmark Tracked by the Global X Uranium ETF (URA)

Lightbridge Corporation, a developer of advanced nuclear fuel technology, announced its inclusion in the Solactive Global Uranium & Nuclear Components Total Return Index effective August 3, 2026. This index is tracked by the Global X Uranium ETF, providing investors passive exposure to the uranium and nuclear sector. The addition places Lightbridge…

Energous’ PowerBridge Pro+ Receives FCC Certification, Advancing Commercialization of the Company’s End-to-End Wireless Power Solution

Energous’ PowerBridge Pro+ Receives FCC Certification, Advancing Commercialization of the Company’s End-to-End Wireless Power Solution

Energous Corporation's PowerBridge Pro+ transmitter has received FCC certification, marking a key regulatory milestone for its wireless power solution. This allows Energous to commercially deploy its end-to-end, battery-free IoT wireless power network infrastructure in U.S. enterprise settings, including warehouses, logistics, manufacturing, and co…

XORTX Appoints New Director

XORTX Appoints New Director

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on therapies for gout and kidney disease, announced the appointment of Depesh Narotam as an independent director on its board. Mr. Narotam brings over 20 years of financial services experience and will serve on the Compensation, Governance and Nominating Committee. The co…

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin Corporation plc announced its Q2 2026 financial results highlighting a 59% year-over-year global volume growth driven by its fully partnered international commercial strategy with Recordati S.p.A. and sustained market presence in the U.S. for VASCEPA. The company achieved lower operating expenses by 38%, completed a $70 million annual cost s…

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics announced the dosing of the first patient in their Phase 3 ALLOHA-2 pivotal trial evaluating TSC-101, a TCR-engineered T cell therapy, in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to prevent relapse post allogeneic hematopoietic cell transplantation. Positive safety and efficacy data from the …

Capital Bank Appoints Jay Como as Chief Operating Officer

Capital Bank Appoints Jay Como as Chief Operating Officer

Capital Bancorp, Inc. (NASDAQ: CBNK) announced the appointment of James 'Jay' Como III as Chief Operating Officer of its subsidiary, Capital Bank. Mr. Como brings over 20 years of financial services leadership with expertise in data governance, automation, and AI from his prior roles at T. Rowe Price and Silicon Valley Bank. His leadership is expec…

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics will report its second quarter 2026 financial results after market close on August 11, 2026, followed by an investor conference call on August 12. The company will update on business developments including advancements in its proprietary Anaphylm and AQST-108 drug candidates. Aquestive operates as both a developer of propriet…

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Corp. has initiated the Phase 2/3 clinical trial of its lead siRNA product candidate, SIL204, targeting locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center. This milestone follows regulatory approvals in Israel and Germany and marks the transition from regulatory preparation to active clinical execution. The…

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva Pharmaceutical Industries Ltd. announced its Q2 2026 results showing a 1% revenue decline year-over-year primarily due to lower generic revenues but a 43% local currency growth in its key innovative brands to over $1 billion, including strong performances from AUSTEDO, AJOVY, and UZEDY. The company raised its 2026 revenue outlook for these inn…

VisionWave Files U.S. Non-Provisional Patent Application for DeepWave RF™, an AI-Powered Subsurface Sensing and Visualization Platform

VisionWave Files U.S. Non-Provisional Patent Application for DeepWave RF™, an AI-Powered Subsurface Sensing and Visualization Platform

VisionWave Holdings, Inc. announced the filing of a U.S. non-provisional patent application for its DeepWave RF™, an AI-driven subsurface sensing and visualization technology designed to provide anticipatory geological formation data ahead of the drill bit. This innovation aims to enhance drilling operations, improve hazard detection, and assist in…

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech AG announced the filing of new patent applications for its BiTAC-TCE and BiTAC-ADC technology platforms and confirmed previously granted patents have cleared opposition. The strengthened patent portfolio includes over 50 patents across 14 countries and aims to provide protection for its core cancer therapy technologies through at lea…

Kirby Corporation Announces Second Quarter 2026 Results

Kirby Corporation Announces Second Quarter 2026 Results

Kirby Corporation reported Q2 2026 earnings per share of $1.67, consistent with the prior year and up 11% sequentially, with total revenues increasing 8% year-over-year to $922.4 million. The marine transportation segment saw revenues rise 9% due to stronger inland and coastal market fundamentals and higher barge utilization. Distribution and servi…